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Abstract
Background: Tobacco abuse is a frequent issue in general practitioners' (GPs') offices, with doctors playing a key
role in promoting smoking cessation to their patients. However, not all smokers are ready and willing to give
up smoking. Thus, a GP focusing on smoking cessation alone might waste the opportunity to improve his
patient’s health by supporting a change in another harmful behaviour pattern. The aim of this study is to
determine whether multi-thematic coaching will lead to higher overall health benefits without resulting in a
reduced rate of successful smoking cessations, compared with a monothematic smoking cessation approach.
Methods: The study is designed as a two-armed, double-blinded, cluster-randomised trial. GPs will be randomly
assigned to the intervention or control group. In the intervention group, GPs will undergo training in patient-
centred coaching, shared decision-making and motivational interviewing. The control group will be trained in
a state-of-the-art smoking cessation algorithm.
GPs will approach adult cigarette-smoking patients and advise those included according to the GP’s group affiliation.
The primary outcome is the between-group difference in the proportion of participants who achieve a beneficial
change in at least one of seven different health-related behavioural dimensions, 12months post baseline. Secondary
outcomes include smoking cessation rates and the patients’ self-perceived smoking-related motivation, self-
efficacy and planning behaviour. Additionally, covariates describing both GPs and patients will be collected
before the start of the intervention, and process outcome measures in compliance with the RE-AIM (Reach
Effectiveness Adoption Implementation Maintenance) framework will be recorded during the ongoing study.
Discussion: Tobacco consumption is still highly prevalent in the general population and often goes hand in
hand with other behaviour patterns with adverse health effects. This study will add to the literature regarding
effective strategies available to GPs to address unhealthy behaviour among their smoking patients beyond
mere smoking cessation counselling. The study will also establish a basis for decisions about further promotion and
dissemination of the coaching under study.
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Background
Tobacco use is a frequent issue in general practitioners'
(GPs') offices, with doctors playing a key role in promoting
smoking cessation to their smoking patients [1]. For this
purpose, standardised brief interventions involving both
counselling and supporting drug therapy have been estab-
lished and evaluated for the primary care setting over the
last years [2, 3].
However, not all smokers are ready and willing to give
up smoking. Therefore, up-to-date stop-smoking pro-
grammes are based on the transtheoretical model of be-
haviour change [4] and thus take the patients’ readiness to
stop smoking [3, 5] into account.
The patient-centred “Health Coaching” programme
[6], developed by the Swiss College for Primary Care
Medicine [7], is based on similar principles. Remarkably,
this programme does not focus on smoking cessation or
any other single health behaviour alone but includes sev-
eral health-related behavioural dimensions in parallel.
Particular emphasis is put on the patient-driven choice
of which topic to address. The Health Coaching
programme has proved its efficiency and practicability in
a clinical trial carried out within the setting of primary
care practitioners in eastern Switzerland [8].
Combining state-of-the-art smoking cessation counselling
with the Health Coaching approach, exploring patients’ mo-
tivation for smoking cessation can be expanded into a more
comprehensive exploration of their readiness to improve
their health in any prioritised topic, hopefully leading to add-
itional benefits beyond those gained from tobacco abstin-
ence. We assume that training the GPs’ communication
skills and incorporating elements of shared decision-making
and motivational interviewing into the counselling process
will lead to higher overall health benefits for smokers. Im-
portantly, this broader perspective of health behaviour
changes should not be paid for in lower smoking cessa-
tion rates in comparison with patients exposed to an
intervention tailored to smoking cessation alone.
Study hypothesis
We hypothesise that multidimensional and patients’
motivation-driven brief interventions by GPs improve
several relevant health outcomes of smokers. We assume
that these improvements surpass the beneficial effects of
monothematic state-of-the-art smoking cessation coun-
selling, and we further assume that the smoking cessa-
tion rates achievable through the novel interventions are
not inferior to those known from state-of-the-art smok-
ing cessation counselling.
To verify these hypotheses, we plan to train the GPs in
the intervention group in how to coach smokers accord-
ing to the Health Coaching programme [6], while the
control group GPs will undergo training in monothe-
matic smoking cessation counselling [5].
Methods/design
Study design and setting
A cluster randomised controlled trial (randomisation on
the GP level) will be conducted with 60 German-speak-
ing GPs from the northern part of Switzerland (see Fig. 1
for the study flow chart). The design and methodology
of the study are partly based on experiences gained from
a previous trial carried out by the last author in eastern
Switzerland [8]. The SPIRIT checklist for this protocol
can be found in Additional file 1.
Eligibility and recruitment of general practitioners
All interested GPs working in outpatient primary care in
the German-speaking part of Switzerland are eligible to take
part in the planned study, irrespective of their contract sta-
tus, their experience in primary care, their age, sex or other
specifics or affiliations. Included GPs must not have had
any previous training in the Health Coaching programme.
In a first step, all members of an interested network of
GPs will be invited through a formal letter from the In-
stitute of Primary Care of the University of Zurich. In
case of insufficient response, email remainders will be
sent out before other doctors’ networks will be included
in the recruitment process, and addresses of potential
participants from existing in-house and freely accessible
federal databases of primary care providers will be
considered.
Cluster randomisation
Participating GPs will be listed chronologically, and
GP characteristics collected prior to their allocation
to either intervention or control arm. Until their re-
quired number is reached (according to the sample
size calculation), the GPs will be allocated to the two
equally sized study arms in blocks of 14–20 GPs
each, by means of a tailored covariate constrained
randomisation procedure [9] with an additional con-
straining criterion regarding potential contamination.
In some more detail, a set of sufficiently balanced al-
locations with regard to the GPs' sex, contract status
and practice type will be constructed and then purged
from contamination-prone allocations (i.e. from those
which put GPs belonging to the same group practice
into different study arms), before randomly drawing
the final allocation to be used in the study. All GPs
from the same group practice will be allocated within
the same block.
The block size was chosen to meet recommenda-
tions by Carter and Hood [10] and also with a view to
training group sizes that can well be handled within the
study centre’s resources. To generate the set of balanced
allocations, we will use the web-based Shiny Balancer [11],
and the additional reduction step will be carried out
manually using Excel’s sorting and filtering capabilities.
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The final random draw will be carried out by a study
nurse not involved in the later data analysis.
Patient recruitment and allocation
All GPs will be asked to approach, consecutively and re-
gardless of the reason for the consultation, current
cigarette smokers at least 18 years old. By insisting on
consecutive targeting of all smokers, we aim to eliminate
selection bias very likely to arise if GPs were allowed to
select patients whom they deem suitable. In order to in-
clude a total of 200 patients, each of the 60 GPs is ex-
pected to recruit three to four patients on average.
Patient inclusion criteria:
 Current cigarette smoker.
 Male or female over 18 years of age.
 Registered as patient in the recruiting GP’s patient
base.
 Capable of judgement with regard to participation in
the study.
 Signed informed consent after being informed.
Patient exclusion criteria:
 Severe general or psychiatric illness (e.g. malignancy,
major depressive episode, dementia, etc.).
 Inability of the participant to follow the procedures
of the study due to other reasons (e.g. language
problems).
 Foreseeable change of general practitioner within 1
year (e.g. due to planned relocation).
Fig. 1 Study flow chart. Small coloured rectangles represent log files and case report forms used to collect data by the study centre (SC) and
from general practitioners (GP) and patients (P). MPA medical assistant (medizinische Praxisassistentin)
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Any participating patient will be assigned to the trial
arm of his GP without involving further randomisation,
and subsequently a set of baseline characteristics (bio-
logical and social traits and particulars of their smoking
habits) will be collected from every patient included.
Since not all GPs might recruit the exact same number
of patients and due to the deterministic allocation of pa-
tients, we expect to record—and document—some inev-
itable imbalance between the trial arms with regard to
patient numbers and (patient) baseline characteristics.
On the other hand, randomness in the GPs' appointment
schedules together with consecutive patient inclusion
and coupled with the patients’ blinding with regard to
the intervention (see next subsection) will translate into
largely randomly composed study clusters. This will pre-
vent extremely imbalanced trial arms.
Blinding
Considering the nature of the interventions, full blinding
of GPs and their patients in the strictest sense is not
possible. However, in order to achieve the highest pos-
sible degree of double-blinding, both GPs and patients
will merely be informed that the intervention is aimed at
promoting beneficial health-related behaviour changes
among smokers, but neither GPs nor patients will be
told which of the two interventions (study or control)
they provide or receive. Before consenting to participate,
the patients will not be offered detailed information
about the intervention they will receive, nor will they
know details about the intervention in the respective
other trial arm during the ongoing study. For those GPs
or patients familiar with clinical studies, a minimum
amount of related information will be available from
registry databases and from the published protocol,
which we consider inevitable.
At the end of the study, GPs will be debriefed and
those in the control arm will be offered training in
Health Coaching too. Ethical approval has been granted
for the blinding procedures.
Intervention
Both the study and the control intervention consist of a
communication training session for the participating
GPs, identical in duration and organisation but different
in content. Training sessions will take 4 h and involve
standardised patients (i.e. actors posing as patients) and
case vignettes tailored to health-related behaviour coun-
selling [12]. The 60 GPs will be split into groups of 7–
10, and each group will then be trained within a short
interval of time.
The 30 control group GPs will receive training in
smoking cessation counselling as put forward by Frei
von Tabak [5].
The training of the 30 GPs in the study arm will cover
the key elements of the Health Coaching programme,
namely patient-centred counselling, shared decision-
making, motivational interviewing and the use of vali-
dated tools from existing health promotion programmes
such as PAPRICA—Physical Activity Promotion in Pri-
mary Care [13], Brief Interventions in Patients with
Risky Alcohol Consumption [14] and aTavola (a short
intervention programme for healthy eating) [15]. Like
their counterparts in the control group, the GPs in the
intervention group will also be trained in smoking cessa-
tion counselling according to Frei von Tabak [5].
The intervention on the patient level will consist of ei-
ther activating and coaching patients in achieving a
beneficial change of their self-selected unhealthy behav-
iour (study intervention group) or of smoking cessation
counselling (control group) in up to three (or occasion-
ally, if necessary, more) sessions. The number of sessions
will depend on progress and the needs of the patients
and will be decided on by both patients and their physi-
cians. Coaching or counselling sessions can be carried
out by medical assistants or nurses provided that they
take part in a training course as already described.
Outcome measures
Primary outcome
The primary outcome is the difference between inter-
vention and control group in the proportion of patients
with any relevant health-promoting change (as defined
in Table 1) in either smoking behaviour, body weight,
physical activity, alcohol consumption, stress level, eat-
ing habits or another self-chosen health-related behav-
ioural dimension. The primary outcome will be collected
(including confirmatory cotinine testing) 12 months after
baseline, and also as secondary outcomes at 1 and 6
months.
The chosen criteria each reflect the lowest level
(cut-off point) of a behavioural change with a proven
health benefit. For rationales behind the choice of these
levels and a justification for choosing “any change” as the
binary primary outcome, see the Discussion section.
Secondary outcomes
Additional secondary outcomes are presented in Table 2.
All secondary outcomes will be compiled at 1, 6 and 12
months after baseline from the same data already col-
lected for the primary outcome, with the exception of
self-efficacy as well as action and coping planning which
are collected during the ongoing counselling on
Likert-type scales with five levels.
Additionally, the covariates presented in Table 3 are
collected, if applicable.
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Process outcomes
In parallel to the ongoing study, additional data will be
collected regarding the implementation, effectiveness
and cost–benefit ratio of the intervention with the aim
of forming a solid basis for decision about further pro-
motion and dissemination of the Health Coaching
programme. The results of the evaluation are expected
to lead to more profound insights into the methodology
of the intervention, in how to optimally train the multi-
plicators and into factors influencing the acceptance of
the intervention by the target population. Furthermore,
the process evaluation comprises an analysis of the costs
generated by the intervention.
We chose the RE-AIM framework [16] by Glasgow et
al. [17] as a comprehensive concept within which to ad-
dress these objectives.
Process outcomes (Table 4) will be evaluated based
on case report and log files used within the actual
trial and also using additional methodology specific to
the respective questions: semi-structured interviews,
questionnaires, telephone interviews and focus group
sessions.
Safety outcomes
Adverse events are defined as any untoward medical oc-
currences in patients after the intervention and do not
necessarily have a causal relationship with study activ-
ities. In particular, the following will be considered as
adverse events:
 Complication of an existing disease.
 Onset of new acute illness.
 Hospitalisation or death.
Adverse events will have to be recorded by the GPs in
the patients’ case report files and reported to the study
centre. The study investigators will decide together with
the respective GP whether there is a plausible connec-
tion between intervention and adverse event.
Follow up
At 1, 6 and 12 months post baseline the patients will re-
port in mail form about their health behaviour status
(regarding smoking, weight, activity, alcohol, diet, stress
and—if applicable—self-chosen behaviour dimension).
Patients claiming to have achieved tobacco abstinence at
12 months after baseline will also be asked to provide a
saliva sample for confirmatory cotinine testing.
In addition to a base compensation, the GPs will be
rewarded with financial compensation for every patient
providing full follow-up data.
Table 1 Definitions of health-relevant behavioural changes
Behaviour dimension: relevance criterion Measuring method References
Smoking: abstinence or reduction of daily number of cigarettes by ≥ 50%
from a baseline of ≥ 15 cigarettes
Self-declaration, confirmatory saliva cotinine test at 12
months for quitters
[18, 27]
Body weight: reduction by ≥ 5% if baseline-BMI≥ 25 kg/m2 Standardised home measurements [28–30, 45, 46]
Physical activity: increase of MVPA by ≥ 90 min per week or increase of
LIPA by ≥ 200min per week, compared to baseline
Recollection-based self-declaration in questionnaire [31–33]
Alcohol: reduction in number of standard drinks (10 g) per week by ≥ 7
drinks from a baseline of ≥ 14 drinks/week
Recollection-based self-declaration in questionnaire [35, 36, 47]
Stress: reduction in score of the Perceived Stress Scale (PSS-10, German
version) by ≥ 5, compared to baseline
Recollection-based self-declaration in validated
questionnaire
[38–41]
Diet: increase by ≥ 10 in score of adapted MedDietScore questionnaire,
compared to baseline
Recollection-based self-declaration in validated
questionnaire
[44, 48]
Participant’s choice: increase by ≥ 2 levels on a 5 level Likert-type scale
(−/0/+/++/+++)
Self-declaration in questionnaire –
BMI body mass index, LIPA light-intensity physical activity, MVPA moderate- to vigorous-intensity physical activity
Table 2 Secondary outcomes
Secondary outcome
Smoking cessation rates in intervention and control groups among
patients with high intrinsic motivation to stop smoking
Smoking cessation rates in intervention and control groups among all
participants
Reduction in number of cigarettes per day, compared to baseline
Weight loss in units of 1 kg, compared to baseline
Increase in physical activity time per week in units of 5 min, compared
to baseline
Reduction in number of standard drinks per week, compared to
baseline, and number of alcohol-free days per week
Reduction in score of the Perceived Stress Scale (PSS-10, German
version), compared to baseline
Increase in score of translated MedDietScore questionnaire, compared
to baseline
Patients’ degrees of motivation and, if applicable, confidence to achieve
and maintain a change in behaviour (self-efficacy)
If applicable: availability of a plan on when and how to take action
(action planning) and existence of a relapse plan (coping planning)
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Sample size calculations
For sample size calculations with respect to the superior-
ity hypothesis, we assume success rates of 40% in the
intervention and 15% in the control group. The 40% as-
sumption is based on results from the preceding study
[8] in which one out of two participants declared sub-
jective improvements in their self-chosen behavioural di-
mension after coaching. The success rate of 15% in the
control group is the sum of a 10% smoking cessation
rate achievable by state-of-the-art smoking cessation
counselling according to Comuz et al. [18] plus an esti-
mated 5% of “spontaneous” effects of smoking cessation
counselling on one of the other behavioural dimensions.
Using α = 5% (two-sided) and β = 10% we calculated a
sample size of 62 participants per equally sized study
arm [19] or 2 · 62 / (1 – 0.25) = 166 participating
smokers in total after factoring in a dropout rate of 25%.
To reflect the correlation structure of the clustered de-
sign, an intra-cluster correlation coefficient (ICC) of 4%
was assumed, which is slightly higher than correspond-
ing values suggested by Parker et al. [20], in order to ac-
count for rare cases of GPs from the same group
practice. This assumption is also backed by (unpub-
lished) calculations from the previous study [8] with
similar cluster structure and outcome. Correction for
the cluster effect increases the sample size to 166 · [1
+ (4 – 1) · 0.04] = 186 or roughly 200 patients, assuming
that a general practitioner is able to recruit four patients.
Finally, allowing for a dropout rate of 15% among general
practitioners, 186 / 4 / (1 – 0.15) = 56 (rounded to the
next higher even number) or roughly 60 general practi-
tioners must be recruited to detect the expected difference
in the primary outcome between the two study arms.
Sample size calculations with respect to the non-infer-
iority hypothesis require additional assumptions. In the
earlier study [8], 12% of smoking or non-smoking GP
patients chose smoking cessation as their primary goal.
For the present study with smoking participants only,
we cautiously assume that in both study arms 25% (i.e.
roughly double this number) are highly motivated to
give up smoking. Based on Lindson-Hawley et al. [21],
we further assume a 40% success rate among the highly
motivated. Using a tentative and rather large non-infer-
iority margin of 10% as in [21] and β = 20%, this results
in an uncorrected sample size of 297 highly motivated
participants per study arm [22] or 2 · 297 / (1 – 0.25) ·
[1 + (4 – 1) · 0.04] · 4 = 3550 participants in total after
correction for clustering and dropouts. Sample size cal-
culations with regard to smoking cessation rates among
all participants lead to even larger samples, not feasible
with available resources. Accordingly, we chose “any
relevant behaviour change” as the primary outcome and
will consider smoking cessation efficacy among the sec-
ondary outcomes.
Data collection procedures
Patients will receive detailed written information on the
aim of the study. After obtaining their written informed
consent, data will then be collected by means of paper
case report forms (CRFs). For every patient, a dossier
with the different CRFs will be created. The forms will
be encoded and the codes stored at each GP’s practice.
Decoding will be possible if case-tracking is needed (in
case of adverse events). Data transfer from paper to elec-
tronic form will be carried out and double-checked inde-
pendently by different research associates.
Statistical analysis
Baseline characteristics (qualitative and quantitative vari-
ables) of GPs and patients will be calculated after recruit-
ment is completed for each arm of the study, with
corresponding 95% confidence intervals where applicable.
Table 3 Covariates
Covariate Source
Biopsychosocial data of general practitioners (age, gender, experience, type of doctor’s practice, data of medical assistants/nurses) GP
Biopsychosocial data of patients (age, gender, marital status, educational level, smoking status of partner) Patient
Characterisation of smoking behaviour (age at onset of smoking, pack-years, number of cigarettes per day, time to first cigarette after
wake up, number of previous attempts to stop smoking)
Patient
Participants’ choice of behavioural dimension GP
Number and duration of coaching/counselling sessions (per patient and in total) GP
Person conducting the coaching/counselling (doctor or specifically trained medical assistant) GP
Type of smoking cessation intervention used GP
Dispense of decision aids GP
Involvement of partner or peers into the coaching/counselling process GP
Perceived partner or peer support Patient
Perceived willingness of partner or peers to achieve the same change in behaviour Patient
GP general practitioner
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Crude success rates (i.e. rates of any relevant
health-promoting behavioural change and smoking cessa-
tion rates) will be compared between intervention and
control groups using χ2-tests after completion of follow
up. As the main analysis, adjustment for cluster effects will
then be performed by (multivariate) hierarchical logistic
regression with individuals as the unit of analysis, grouping
by GP as the random effect and covariates (including the
balancing variables) as independent fixed effects.
Changes in outcome measures that do not meet the
criteria for clinical relevance defined in Table 1 will be
described and presented graphically (density plots,
Table 4 Process outcomes
Process evaluation outcome Source
Reach: proportion and representativeness of individuals receiving the intervention (individual level)
Rate of smokers among the GP's patients GP
Rate of smokers invited to participate GP
Rate of refusals, with reasons GP
Patient dropout rate, with reasons GP
Patients’ characteristics and representativeness See covariates
Efficacy: success rates of the intervention (including satisfaction outcomes) under study conditions (individual level)
Behaviour change rates See outcomes
Changes in self-efficacy and planning See outcomes
Patients’ current overall satisfaction with coaching programme Patient
Adoption: proportion and representativeness of organisations willing to adopt the intervention, with consideration of enablers and barriers to adoption
(organisational level)
Rate of GPs invited to participate SC
Rate of refusals, with reasons SC
GP dropout rate, with reasons SC
GPs' characteristics and representativeness See covariates
Involvement of medical assistants/nurses See covariates
Assistants'/nurses' characteristics See covariates
Assessment of GPs' precognitions, understanding of coaching/counselling concept and increase in knowledge and skills,
evaluation/
rating of coaching/counselling concept and structure of training, recommendation to colleagues
GP
Time required for coaching/counselling See covariates
Rating of coaching/counselling tools in matters of usefulness and manageability, enabling factors and barriers in coaching/
counselling as perceived from practical experience
GP
Overall assessment: benefit for daily practical work, most crucial aspects (success factors and pitfalls), suggestions for
improvement, overall satisfaction
GP
Implementation: extent to which the intervention is implemented under real-world conditions—patient adherence (individual level) and adherence
of staff to study protocol (organisational level)
Number of coaching/counselling sessions per patient See covariates
GPs'/assistants'/nurses' attitudes, competences and (mental) barriers towards/in/to delivering the interventions GP
Changes in contents or duration of coaching/counselling elements during the ongoing trial GP
Completeness/integrity of data reported by GPs SC
Costs arising from expenditure of coaching time SC
Maintenance: sustainability of intervention over time—relapse rates (individual level) and integration of intervention into institutional routine
(organisational level)
Upholding of beneficial behaviour at 12 months after end of follow up Patient
Number of GPs trained in HC until 12 months after end of follow up HC registry
Number/frequency and quality/intensity of coaching over a period of 12 months beyond follow up GP
Response among experts and media coverage Experts, media
Maintenance costs GP
GP general practitioner, HC Health Coaching programme, SC study centre
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histograms), compared across study arms using χ2-tests
or t-tests and adjusted by random-effects regression
models analogous to those used for success rate compar-
isons, but with the respective behavioural change mea-
sures as dependent variables.
All analyses will be conducted following an intention-
to-treat (ITT) approach (i.e. outcome data will be obtained
from all participants and analysed “as randomised”). Missing
values will be replaced by standard multiple imputation (MI)
as recommended by Ma et al. [23] for clustered designs with
variance inflation factors < 3. Non-responder imputation
(NRI; i.e. conservatively treating all missing values as fail-
ures) will be used within the scope of sensitivity analyses.
Qualitative information from the process evaluation
will be analysed using common coding techniques for
qualitative data. A coding tree will be established de-
ductively based on pre-determined domains of interest
and refined by inductively adding codes where appropri-
ate. Results will be reported in percentages or categories.
Proportions or mean values of different subgroups will
be compared using χ2-tests or t-tests.
Timeframe
Fig. 2 shows for the SPIRIT diagram. The first GP was
recruited in mid-2018. Patients’ eligibility screening and
patient inclusion started in the fourth quarter of 2018
with the desired goal of including an average of about
one patient per month per GP. Follow up will last for
12 months for each patient.
Patient informed consent
Previous to study participation, the patients will receive
written or verbal information about the content and ex-
tent of the planned trial from their individual GPs. In
the case of acceptance, they will sign the informed con-
sent form.
Data security/disclosure of original documents
The patient names and all other confidential infor-
mation fall under medical confidentiality rules and
will be treated according to appropriate Federal Data
Security Laws. For contact maintenance and case
tracking (e.g. in the case of adverse events), the pa-
tients’ identities will be known to a study nurse not
involved in the analysis of the patient data. The pa-
tient names will not be accessible to the scientific
study staff.
Fig. 2 SPIRIT diagram for trial stages of enrolment, intervention and outcome assessment. GP general practitioner, RGP recruiting of GPs, TGP
training of GPs, Cons0 consultation 0, Co1–3 coaching/counselling 1–3, FUp1–3 follow up 1–3, alaCo after coaching/counselling of last
patient, pFUp post follow up, Resp expert response
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Discussion
Justification of the binary primary outcome
Any change
To our knowledge, the suggested composite outcome
has not been used or validated before. It is largely un-
known how—in terms of health benefits—a change in
some behaviour dimension A compares with a change in
another dimension B, and we know of no standardisa-
tion procedure to make sizes of changes comparable
over different dimensions. To make matters worse, dif-
ferent behaviour changes are measured on different
scales, and health benefits have been associated with ab-
solute changes in some measures but with relative
changes in others. We believe that, given these impon-
derabilities, the binary outcome “any relevant change in
any component dimension” keeps the utmost possible
intrinsic validity, since, firstly, the validity of the individ-
ual relevance criteria has been demonstrated and,
secondly, no further assumptions on interaction or com-
parability of different behaviour changes are needed.
Moreover, while using a dichotomous primary outcome
measure inevitably incurs some loss of information, the
study findings will be all the more meaningful for clin-
ical care, provided that a statistical difference will be
found [24]. The loss of information will be compensated
for by analysing secondary outcomes.
Time aspects
Evaluating primary and secondary outcomes at 1, 6 and
12months after baseline will allow capturing both
easy-to-achieve early and hard-to-achieve late behavioural
changes. The first two points of time were chosen in ac-
cordance with Lindson-Hawley et al. [21] and the last two
correspond to the Russel Standard [25] for smoking cessa-
tion trials. Data collection at three different times will also
provide information on the sustainability of beneficial be-
haviour changes at the level of the study collective, al-
though not at the individual level. Duration of upkeep of
beneficial behaviour patterns was not included among the
primary or secondary outcomes because we do not know
whether, for example, one sustained change is preferable
over two different changes of short duration. However, we
will assess the persistence of individual successes beyond
follow up as part of the process evaluation.
Rationales for the choice of relevance criteria
Smoking
Within the present study, we consider halving the daily
number of cigarettes as sufficiently associated with
health benefits. We realise that the evidence supporting
this criterion is not overwhelming, and there might even
be no benefit in terms of mortality at all [26]. On the
other hand, the rate of smoking-related cancers or lung
cancers was considerably lower even in Tverdal and
Bjartveit’s study [26], although not significantly so as in
Godtfredsen et al. [27]. The two studies are somewhat
contradicting in terms of size and significance of the ef-
fect, which suggests that a reduction by 50% might rep-
resent the limit of detection of health benefits from
smoking reduction.
Body weight
A pro-rata weight loss of 5% is widely accepted as “clin-
ically relevant” or “clinically significant”, see for example
Stevens et al. [28], and numerous studies have been car-
ried out using this criterion [29, 30]. Swift et al. [29], for
example, demonstrated a significant beneficial effect on
insulin levels whereas other cardiovascular risk factors
showed short of significant changes in the desirable di-
rections after clinically significant weight loss due to a
weight reduction intervention.
Physical activity
Current guidelines recommend a minimum of 150 min
of physical activity per week of at least moderate inten-
sity (corresponding to ≥ 7.5 MET∙h). Beneficial health ef-
fects have been satisfactorily demonstrated for roughly
60% of this amount, for example by Wen et al. [31].
See also the recommendations of the US Physical Activ-
ity Guidelines Advisory Committee [32]. According to
both sources, additional health effects have been shown
for further activity increases by the same amount.
Equivalent amounts or equivalent additional amounts of
physical activity can be achieved with similarly beneficial
results at lower intensities but with longer duration [33].
The obvious and tempting idea of using tracking de-
vices had to be discarded on the grounds of practicabil-
ity (distribution and maintenance of the devices),
methodological considerations (recording of baseline ac-
tivity before the first coaching or counselling session)
and due to the sheer costs of providing appropriate sen-
sors to all 200 participants. Out of consideration for the
participants (who need to document their health behav-
iour in all seven dimensions) we also decided against
relying on diaries to capture the amount of physical ac-
tivity. This decision is backed by Timperio et al. [34],
who point out that the use of physical activity logbooks
does not increase estimates of validity of 7-day recall
physical activity questionnaires.
Alcohol consumption
The cardioprotective role of alcohol consumption has
most probably been overestimated in the past. Recent
research, for example, by Rehm et al. [35] suggests a
dose–risk relationship with a less pronounced J-shape
compared to older results. According to Rehm et al.,
health risks exceed benefits for any amount of alcohol
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consumed beyond 10 g per day, irrespective of sex and
age. The 2000 WHO guidelines [36] show increasing
all-cause mortality estimates for intake classes starting
from 10 g/day with class widths of 10 g/day. Our choice
of criterion reflects both the cut-off point as well as this
magnitude of change, but is based on a weekly assess-
ment as used in most current guidelines on alcohol
consumption.
We decided against extending the criterion to cover
drink-free days because their benefit is still highly debat-
able and probably dependent on the total amount con-
sumed [37]. In accordance with measuring physical
activity and because the effort was again not deemed
reasonable for the patients, we do not intend to use diar-
ies or logbooks that would have to be filled in over
several days.
Stress level
The Perceived Stress Scale (PSS-10) [38] was chosen for
its widespread recognition and frequent use in psycho-
metric research, for the availability of a free and vali-
dated German translation, and for its briefness and
practicability. Furthermore, the PSS-10 is one of only
few scales for which we were able to find satisfactory
data describing quantitatively the score changes after
stress relief interventions or the association between
changes of the score and health outcomes.
Two relatively small studies by Wiegand et al. [39] and
Kirby et al. [40], both carried out in non-clinical com-
munity settings and with baseline PSS-10 scores of ap-
proximately 24 (scale ranges from 0 to 40), found mean
decreases in the total PSS-10 scores by about 6.3–9 after
stress management interventions of 14 weeks or 10 days,
respectively, and about 4.1–5 in the control groups.
Based on these data we consider a score reduction by at
least 5 as a relevant change. This choice gets some em-
pirical support from results of validation studies that
established standard deviations in the order of our cri-
terion [41] and showed that our criterion roughly corre-
sponds to the mean difference between psychiatric
outpatients and the general population [42].
Eating habits
Concerning food intake there is a vast number of short
dietary assessment instruments and screeners available
[43] but none of them has prevailed as a generally recog-
nised standard to capture overall diet quality in the pri-
mary care setting. The ideal tool was expected to cover
the patient’s diet as a whole and without including food
items unusual in a typical “local” diet. Furthermore, it
was required that laypeople would be able to complete it
within reasonable time and without expert knowledge,
for example, about different nutritional components of
various foods. Lastly, and if at all possible, it had to be
validated with respect to some quantifiable morbidity or
mortality outcome. The MedDietScore [44] meets these
requirements best.
Again, we do not intend to use food diaries for similar
reasons as mentioned earlier with respect to physical ac-
tivity and alcohol consumption. Moreover, we will not
try and assess eating habits beyond the mere compos-
ition of the diet because we do not know of any vali-
dated tools to cover both composition and additional
aspects.
Strengths and limitations
The pragmatic study design allows for recognising
beneficial changes in any health-related behaviour.
However, there are some important limitations. The
necessity to collect data regarding seven different be-
haviour dimensions requires a significant effort on the
part of the participants. Overstraining their cooper-
ation would most likely result in losses to follow up
and poor data quality. In the context of the present
study, it is therefore not possible to capture all behav-
iour changes with the highest desirable objectivity.
Even though validated measuring instruments will be
used as far as possible, recall and desirability bias as
well as interpretation bias cannot fully be ruled out.
Moreover, some of the chosen cut-off levels for clin-
ical relevance are somewhat debatable. Lastly, we will
not be able to completely avoid the selection of suit-
able cases either on the level of GPs or on the level
of patients, even though the consecutive recruitment
of patients will prevent the selection of “good risks”
by their GPs up to a certain extent.
Desired impact
The knowledge gained from this study is likely to influ-
ence the way GPs deal with harmful behaviour patterns
of their patients who smoke. It has the potential to in-
crease care provision for morbidity and mortality risk
behaviour beyond mere smoking cessation support. If
shown to be effective and feasible, a coaching strategy as
set out in the Health Coaching programme and adopted
in this study, focusing on shared decision-making and
the promotion of the patients’ intrinsic motivation to
tackle their individual health problems, could ultimately
reduce the high prevalence of risk behaviours in the
smoking population.
Trial status
Patient recruitment had not yet started at the time of
the first submission in February 2018 and is planned to
take part from late 2018 until mid-2019.
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